immatics is a clinical-stage biopharmaceutical company dedicated to developing advanced therapeutic vaccines that are active against cancers with a high unmet medical need.
immatics' proprietary basis for the identification of tumor-associated peptides (TUMAPs) enables the development of novel anti-cancer vaccines.
immatics is currently working on the development of new substances for a number of specific cancer types. Our most advanced product is currently been developed in a Phase III clinical trial for kidney cancer. A second product targeting colorectal cancer has just completed a large Phase II clinical trial and a third cancer vaccine has recently entered two Phase I clinical trials in brain cancer. We also have active earlier programs in several other tumor types including gastric cancer and non-small-cell lung cancer.
immatics was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen (Hans-Georg Rammensee).
To read more, please download the complete "immatics Fact Sheet"!